Clinical care of a child with hemophilia A and inhibitors

Surbhi Saini; Amy L. Dunn

doi:10.1007/978-3-030-31661-7_2

Clinical care of a child with hemophilia A and inhibitors

Research output: Chapter in Book/Report/Conference proceeding › Chapter › peer-review

Abstract

Approximately 30% of patients with severe hemophilia A develop inhibitory antibodies to factor VIII. Patient-related and treatment-related factors have been implicated in inhibitor development. Inhibitor development is associated with significant morbidity, and decreased quality of life, and is currently the most challenging complication in the management of patients with hemophilia. Hemostatic bypassing agents are used to control bleeding episodes in patients with inhibitors, while the cornerstone of management is inhibitor eradication by immune tolerance. Newer nonfactor products are rapidly changing the landscape of inhibitor management.

Original language	English
Title of host publication	Pediatric Bleeding Disorders
Subtitle of host publication	A Clinical Casebook
Publisher	Springer International Publishing
Pages	13-23
Number of pages	11
ISBN (Electronic)	9783030316617
ISBN (Print)	9783030316600
DOIs	https://doi.org/10.1007/978-3-030-31661-7_2
State	Published - Jan 1 2020

Keywords

Bypassing agents
Hemophilia A
Immune tolerance therapy
Inhibitors

Access to Document

10.1007/978-3-030-31661-7_2

Cite this

@inbook{d8bdaf17ec4c4db0b7433acaf3b29242,

title = "Clinical care of a child with hemophilia A and inhibitors",

abstract = "Approximately 30% of patients with severe hemophilia A develop inhibitory antibodies to factor VIII. Patient-related and treatment-related factors have been implicated in inhibitor development. Inhibitor development is associated with significant morbidity, and decreased quality of life, and is currently the most challenging complication in the management of patients with hemophilia. Hemostatic bypassing agents are used to control bleeding episodes in patients with inhibitors, while the cornerstone of management is inhibitor eradication by immune tolerance. Newer nonfactor products are rapidly changing the landscape of inhibitor management.",

keywords = "Bypassing agents, Hemophilia A, Immune tolerance therapy, Inhibitors",

author = "Surbhi Saini and Dunn, {Amy L.}",

year = "2020",

month = jan,

day = "1",

doi = "10.1007/978-3-030-31661-7_2",

language = "English",

isbn = "9783030316600",

pages = "13--23",

booktitle = "Pediatric Bleeding Disorders",

publisher = "Springer International Publishing",

}

TY - CHAP

T1 - Clinical care of a child with hemophilia A and inhibitors

AU - Saini, Surbhi

AU - Dunn, Amy L.

PY - 2020/1/1

Y1 - 2020/1/1

N2 - Approximately 30% of patients with severe hemophilia A develop inhibitory antibodies to factor VIII. Patient-related and treatment-related factors have been implicated in inhibitor development. Inhibitor development is associated with significant morbidity, and decreased quality of life, and is currently the most challenging complication in the management of patients with hemophilia. Hemostatic bypassing agents are used to control bleeding episodes in patients with inhibitors, while the cornerstone of management is inhibitor eradication by immune tolerance. Newer nonfactor products are rapidly changing the landscape of inhibitor management.

AB - Approximately 30% of patients with severe hemophilia A develop inhibitory antibodies to factor VIII. Patient-related and treatment-related factors have been implicated in inhibitor development. Inhibitor development is associated with significant morbidity, and decreased quality of life, and is currently the most challenging complication in the management of patients with hemophilia. Hemostatic bypassing agents are used to control bleeding episodes in patients with inhibitors, while the cornerstone of management is inhibitor eradication by immune tolerance. Newer nonfactor products are rapidly changing the landscape of inhibitor management.

KW - Bypassing agents

KW - Hemophilia A

KW - Immune tolerance therapy

KW - Inhibitors

UR - http://www.scopus.com/inward/record.url?scp=85088475380&partnerID=8YFLogxK

U2 - 10.1007/978-3-030-31661-7_2

DO - 10.1007/978-3-030-31661-7_2

M3 - Chapter

AN - SCOPUS:85088475380

SN - 9783030316600

SP - 13

EP - 23

BT - Pediatric Bleeding Disorders

PB - Springer International Publishing

ER -

Clinical care of a child with hemophilia A and inhibitors

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this